Shares of Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $3.89 and last traded at $4.01, with a volume of 54,952 shares traded. The stock had previously closed at $4.56.

AGLE has been the topic of a number of analyst reports. Wells Fargo & Co. initiated coverage on Aeglea Biotherapeutics in a research report on Monday, May 2nd. They set an “outperform” rating on the stock. BMO Capital Markets initiated coverage on Aeglea Biotherapeutics in a research report on Monday, May 2nd. They set an “outperform” rating and a $19.00 target price on the stock. Finally, Needham & Company LLC initiated coverage on Aeglea Biotherapeutics in a research report on Monday, May 9th. They set a “buy” rating and a $18.00 target price on the stock.

The company has a 50-day moving average price of $5.99 and a 200-day moving average price of $7.42. The stock’s market capitalization is $56.46 million.

Aeglea Biotherapeutics (NASDAQ:AGLE) last posted its quarterly earnings results on Friday, May 20th. The company reported ($7.10) EPS for the quarter, missing the consensus estimate of ($0.42) by $6.68. Analysts anticipate that Aeglea Biotherapeutics Inc. will post ($2.35) EPS for the current fiscal year.

In related news, major shareholder Bioventures Ltd Novartis purchased 300,000 shares of the stock in a transaction dated Tuesday, April 12th. The shares were acquired at an average cost of $10.00 per share, for a total transaction of $3,000,000.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Anthony Quinn purchased 10,000 shares of the stock in a transaction dated Tuesday, April 12th. The shares were bought at an average price of $10.00 per share, for a total transaction of $100,000.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $100,000. The disclosure for this purchase can be found here.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.